Nektar Therapeutics shares jumped 35.3% in extended trading Monday after the company said it would release topline results ...

Nektar Therapeutics said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin on Tuesday. Shares climbed 27% to $12.15 in after-hours trading Monday.

Shares of Nektar Therapeutics soared after the company said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin. The stock was up 31% at $12.49 in Monday's ...

Investing.com -- Nektar Therapeutics (NASDAQ: NKTR) stock surged 20% following the company’s announcement that it will present top-line data from its REZOLVE-AD Phase 2b clinical trial for atopic ...

Shea butter has historically been used for skin ailments for centuries. Learn the wide range of shea butter benefits and how ...

Three months after the US Sofdra launch, prescriptions have exceeded Botanix Pharmaceuticals' expectations. What are they ...

The biopharmaceutical company said Friday that the U.S. Food and Drug Administration has extended the review period by three months to Sept. 19, giving it more time to review additional chemistry, ...

Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura ® ...

Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 biotech stocks screaming a buy. On June 17, the company delivered positive ...

An itchy scalp may be related to your hair-washing schedule, but may stem from various other causes, including skin ...

Discover life-changing eczema treatments and remedies that provide real relief. From prescription breakthroughs to natural ...

Discover a study that found that children with early AD were more likely to develop food allergies, whereas those with later ...